AbstractBackgroundBotulinum toxin type A (BoNT‐A) and botulinum toxin type B are the only two serotypes of botulinum toxin currently available for therapeutic use. Recently, botulinum toxin type E (BoNT‐E) has been explored for clinical use due to its pharmacological properties. BoNT‐E has a faster onset of action and a shorter duration of effect compared to BoNT‐A.MethodsA literature review of BoNT‐E in terms of its mechanism of action, efficacy, and treatment applications.ResultsBoNT‐E has thus far demonstrated efficacy in the treatment of glabellar frown lines. Additional potential applications include the treatment of focal muscle pain and the reduction of postoperative scars.ConclusionBoNT‐E products have the potential to fulfill an unmet need for patients considering first‐time use of botulinum toxin for esthetic purposes and for patients seeking rapid results.